Lipidic systems for in vivo siRNA delivery
Sherry Y Wu1, Nigel A J McMillan
1Diamantina Institute for Cancer, Immunology and Metabolic Medicine, University of Queensland, Level 4, R-Wing, Princess Alexandra Hospital, Ipswich Rd, Buranda, QLD, 4102, Australia.
Abstract:
The ability of small-interfering RNA (siRNA) to silence specific target genes not only offers a tool to study gene function but also represents a novel approach for the treatment of various human diseases. Its clinical use, however, has been severely hampered by the lack of delivery of these molecules to target cell populations in vivo due to their instability, inefficient cell entry, and poor pharmacokinetic profile. Various delivery vectors including liposomes, polymers, and nanoparticles have thus been developed in order to circumvent these problems. This review presents a comprehensive overview of the barriers and recent progress for both local and systemic delivery of therapeutic siRNA using lipidic vectors. Different strategies for formulating these siRNA-loaded lipid particles as well as the general concern about their safe use in vivo will also be discussed. Finally, current advances in the targeted delivery of siRNA and their impacts on the field of RNA interference (RNAi)-based therapy will be presented.
Insights
Lipid-based delivery systems enhance the therapeutic potential of small-interfering RNA (siRNA) by overcoming challenges in gene silencing. This review explores lipidic vectors for effective siRNA delivery in RNA interference (RNAi) therapy.
Area of Science:
- Biotechnology
- Molecular Biology
- Pharmacology
Background:
- Small-interfering RNA (siRNA) holds promise for gene function studies and treating diseases.
- Clinical applications are limited by in vivo delivery challenges: instability, poor cell entry, and pharmacokinetics.
- Liposomes, polymers, and nanoparticles are explored as delivery vectors.
Purpose of the Study:
- To provide a comprehensive overview of barriers and progress in therapeutic siRNA delivery using lipidic vectors.
- To discuss formulation strategies for siRNA-loaded lipid particles.
- To examine advances in targeted siRNA delivery for RNA interference (RNAi) therapy.
Main Methods:
- Review of current literature on lipidic vectors for siRNA delivery.
- Analysis of formulation strategies and safety considerations for in vivo use.
- Discussion of targeted delivery advancements.
Main Results:
- Lipidic vectors show significant progress in overcoming siRNA delivery barriers for both local and systemic applications.
- Various formulation strategies exist for creating effective siRNA-loaded lipid particles.
- Targeted delivery approaches are advancing RNAi-based therapeutics.
Conclusions:
- Lipidic vectors are crucial for advancing siRNA-based therapies by improving delivery efficiency and stability.
- Safe and effective in vivo delivery of siRNA is achievable through optimized lipidic formulations.
- Continued innovation in targeted delivery will broaden the impact of RNAi therapeutics.
Related Concept Videos
02:30siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
02:15Experimental RNAi
01:24Modified-Release Drug Delivery Systems: Site-Targeted